Stocks Health care COGT
NASDAQ · Health careCogent Biosciences, Inc. (COGT)
It posted a net loss of $377.2M. In fiscal 2025 capital spending exceeded operating cash flow by $266M. At June 30, 2026 it held $181.2M in cash against $223.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Cogent Biosciences, Inc. does
Cogent Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COGT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$328.9M | -$2.16 | -$266M |
| 2024 | n/a | -$255.9M | -$1.94 | -$208.4M |
| 2023 | n/a | -$192.4M | -$1.94 | -$156.4M |
| 2022 | n/a | -$140.2M | -$1.73 | -$125.5M |
| 2021 | n/a | -$72.3M | -$1.35 | -$60.5M |
| 2020 | $7.9M | -$74.8M | -$11.70 | n/a |
Latest SEC filings
What Cogent Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 2, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Other event 8-K
- August 10, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 10, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 11, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
Questions about COGT
What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker COGT.
Is Cogent Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $377.2M.
When did Cogent Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 2, 2026.
Similar companies
Follow COGT
Get an email when Cogent Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow COGT: get an email when it filesWhere the numbers come from
Financial figures are the values Cogent Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.